Chemokines and NAFLD
Chemokines, a family of small and highly conserved proteins (with molecular weights ranging from 8 to 12 kDa), are involved in multiple biological processes, including chemotaxis, 21 leukocyte degranulation, 22 hematopoiesis 23 and angiogenesis, 24 and mediate immune cell trafficking and lymphoid tissue maturation. 25, 26 Although the chemokines have a highly conserved and three-stranded β-sheet/α-helix tertiary structural fold, their quaternary structures vary as compared with their subfamily. As indicated in Figure 2 , according to the sequential positions of the first two cysteine residues, chemokines are divided into four main subtypes: CC-chemokines, CXC-chemokines, C-chemokines and CX3C-chemokines, 26, 27 and possess tiny differences in structure. In CC and CXC chemokines, the first two cysteines are adjacent (CC motif) or separated by one amino acid residue (CXC motif). C chemokines lack the first and third of the cysteines, and CX3C chemokines have three amino acids between the first two cysteine residues. 27, 28 In terms of the chemokine specific binding with different receptors and vice versa, a superfamily of chemokines has been presented 26, [28] [29] [30] (Table 1) . As shown in Figure 3 , the chemokine receptors, 7-transmembrane G protein-coupled receptors consist of an N-terminus outside the cell surface, three extracellular and three intracellular loops as well as a C-terminus in the cytoplasm. 28, 31 The interaction between chemokines and their receptors has a key role in the occurrence of liver diseases.
The liver tissues are enriched by various kinds of immune cells including Kupffer cells (KCs), resident macrophages, natural killer (NK) cells and The 'multiple hit' hypothesis for the progression of NAFLD and natural history of NAFLD: dietary habits, environmental and genetic factors result in the development of insulin resistance, obesity with adipocyte proliferation and changes in the gut microbiome. Insulin resistance leads to increased hepatic DNL and dysfunction of adipose tissue and adipocyte. Fat accumulates in the liver in the form of TG. Contemporarily, this happens with increased lipotoxicity from high levels of FFAs, free CH and other lipid metabolites, which induce mitochondrial dysfunction with oxidative stress and production of ROS and ER stress with activation of UPR. All these factors lead to hepatic inflammation, apoptosis and fibrosis. Also, the altered gut microbiome results in more production of FFAs and CH and increases small bowel permeability. Increased fatty acid absorption causes the activation of inflammasome such as LPS, and the release of proinflammatory cytokines such as IL-6 and TNF-α. 39 In contrast, CCR2-deficient mice display a decreased accumulation of inflammatory cells in the liver, 39,41 and the inhibition of the CCL2-CCR2 axis causes reduced hepatic fibrosis in experimental fibrosis models. 37,39 Propagermanium, as a CCR2 inhibitor, is reported to prevent insulin resistance, steatosis 42,43 and NASH. 44 The CCL2-CCR2 axis also mediates the liver injury to lead to parenchymal cell necrosis or apoptosis by release of ROS and activation of HSCs and macrophages. 45 It has been reported that patients with HCC have a lower serum level of CCL2 than cirrhotic patients. 46 Other CC-chemokines and their receptors also participate in the progression of NAFLD. The expression of CCL5 and its receptors CCR1 and CCR5 is increased in liver macrophages and HSCs and facilitates liver fibrogenesis. 49 CCL5 secreted by HSCs directly induces steatosis and proinflammatory factors in healthy hepatocytes through interacting with its receptor, CCR5. 50 CCR1 and CCR5 mediate profibrogenic effects in bone marrow-derived cells and resident liver cells, and promote the migration of HSCs through a redox-sensitive and PI3K-dependent pathway. 51 Figure 2 . The structure of chemokines. The structures of chemokines are similar with at least three β-pleated sheets (indicated as β1-3) and a C-terminal a-helix. In the CXC chemokine family, the two cysteines nearest the N-termini are separated by a single and variable amino acid. In the CC chemokine family, the two cysteines nearest the N-termini are adjacent. In the C chemokine family, only one cysteine is near its N-terminus. The CX3C chemokine has a typical chemokine-like structure. The two cysteines nearest the N-termini are separated by three amino acids. In addition, the chemokine domain occurs at the end of a long stalk which is largely replaced by mucin-like carbohydrates. The protein is fixed in the membrane and has a short cytoplasmic domain. 4 journals.sagepub.com/home/tag 
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Other names of chemokine Receptors CCL3 (MIP-1α) and CCL4 (MIP-1β) are upregulated in mouse liver fibrogenesis models and human fibrosis samples, favor mouse liver fibrosis via increasing proliferation and migration of HSCs, and associate with stellate cell activation and liver immune cell infiltration. 48 Inhibition of CCR1 and (or) CCR5 represses the progression of liver fibrosis in mice. 51, 52 Moreover, pharmacologic inhibition of CCL5 facilitates fibrosis regression in mice. 52 Beyond that, the serum levels of CCL4 and CCL5 are higher in HCC patients than those in cirrhotic patients, indicating that CCL4 and CCL5 as inflammatory chemokines are used to predict the presence of HCC. 46 Additionally, CCL1-CCR8 and CCL25-CCR9 pathways also play critical roles in promoting liver fibrosis by recruiting macrophages. 36, 59 Recent studies have shown that the expression of CCL20 is increased in patients with NAFLD fibrosis. 53 CCL20 and its exclusive receptor CCR6 contribute to cholestatis and HCC. Accumulation of immune cells in adipose tissue (AT) causes obesity-associated inflammation, insulin resistance 46 Increased expression of CXCL5 is correlated with neutrophil infiltration and poor prognosis in patients with HCC. 60 CXCR2, a CXCL5-specific receptor, is at a high level in many cancer cells and is related to tumorigenesis, tumor angiogenesis and metastasis. [61] [62] [63] The CXCL5-CXCR2 axis gives rise to cell spreading by inducing EMT via activation of the PI3K/Akt/GSK-3β/Snail signaling pathway. 64 CXCL8, known as interleukin (IL)-8, is a proinflammatory CXC chemokine with the properties of tumorigenicity and angiogenesis in cancer. 93 The CXCL8 level is increased in HCC tissues and cell lines, and coexpression of HIF-1α and CXCL8 induces HCC progression and metastasis via activation of the AKT/mTOR/STAT3 pathway, indicating that CXCL8 is a prognostic marker and a potential target for HCC. 65 Macrophages are a major component of tumor stroma involved in HCC progression. Recently, macrophages activated by co-cultured liver cancer cells produce higher levels of CXCL8, induce CXCL8/miR-17 cluster, and promote HCC cell proliferation and metastasis. 66 Additionally, tissue-derived fibroblasts, CCL2, CXCL1, and CXCL8 are upregulated in HCC and accelerate its progression. 47 CXCL10 belongs to the ELR-negative CXC family. In the liver, CXCL10 is mainly secreted by the liver sinusoidal endothelium and hepatocytes in areas of lobular inflammation. The CXCL10 serum level is associated with the severity of lobular inflammation and acts as an independent risk factor for NASH patients. CXCL10 induces inflammation, oxidative stress and fibrosis in experimental steatohepatitis via activation of the nuclear factor kappa-lightchain-enhancer of activated B-cells (NF-κB) pathway. 73 In addition, CXCL10 promotes steatosis by stimulating lipogenesis 74 and cholesterol (FFC) diet-induced macrophage-associated hepatic injury and fibrosis. 75 As a proinflammatory factor, CXCL10 is implicated in each phase of NASH development. 73 CXCL9 serum level is also associated with genotypes and severity of liver fibrosis in patients. 67, 68 CXCR3 is the receptor of multiple ligands such as CXCL4, CXCL9, CXCL10 and CXCL11, 69 and displays a role in the development of steatohepatitis. 70, 75 CXCR3 contributes to the expansion of liver inflammation to the parenchyma by inducing endothelial transmigration and T-cell chemotaxis to the liver lobule. 71 Increased expression of CXCR3 is confirmed in human NAFLD liver tissues and experimental steatohepatitis models, while the blockade of CXCR3 reverses the established steatohepatitis. 70 CXCR3 promotes cholesterol-induced steatohepatitis and NASH, 75 facilitates lipid accumulation, inflammatory cell infiltration and ER stress, 70 and induces macrophage infiltration and Th1 and Th17 immune response in steatohepatitis. 70, 72 CXCL11 serum level is increased in patients with liver fibrosis, nonalcoholic cirrhosis and high portal pressure, and is used to predict long-time survival of cirrhotic patients bearing transjugular intrahepatic portosystemic shunts. 76 CXCL12, known as stromal-derived factor 1 alpha (SDF1α) is the ligand of CXCR4 and CXCR7. The CXCL12-CXCR4 axis promotes proliferation, survival, invasion, and metastasis, 77 and mediates interstitial fluid flow to enhance the invasion in HCC cells via the MEK/ERK pathway. 78 
Application prospect
In terms of the role of chemokines and their receptors in the pathogenesis of liver diseases, some therapeutic strategies for targeting chemokines and their receptors may highlight a new direction for the treatment of patients with liver diseases. As showed in Table 3 , pharmaceutical inhibition of CCR2 contributes to an inhibition of liver inflammation and fibrosis by preventing infiltration of Ly6C-positive macrophages. 94 Congruously, previous studies showed that pharmacological inhibition of CCL2 or CCR2 significantly ameliorates insulin resistance, steatosis and inflammation in several metabolic disease models. 95 Of note, cenicriviroc (CVC), a CCR2 and CCR5 antagonist, has the potential to exert anti-inflammatory and antifibrotic activity in animal models. In a phase II study, in obese adults with NASH, CVC does not achieve the ideal 
